SGLT2 inhibitors have demonstrated hepatic benefits, particularly in patients with T2DM and MASH, as several studies show that these agents significantly reduce alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma‐glutamyl transferase (GGT) levels, alongside reductions in hepatic fat content [11-15]. Here, SLC5A2 is linked to type 2 diabetes mellitus.